EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-world experience with filgotinib for rheumatoid arthritis in Germany

Olaf Schultz, Christoph Fiehn, Christian Kneitz, Nils Picker, Daniel Kromer, Monia Zignani, Francesco De Leonardis, Hans-Dieter Orzechowski, Margot Gurrath, Klaus Krüger

Zeitschrift für Rheumatologie · 2025-02 · 84 (1) · 39-47

DOI: 10.1007/s00393-024-01506-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Zeitschrift für Rheumatologie, online erschienen am 30.04.2024. Verfasst von Olaf Schultz und 9 weiteren Autor:innen. Beteiligte Einrichtung: ACURA Kliniken Baden-Baden/Rheumazentrum, Rotenbachtalstraße 5, 76530, Baden-Baden, Germany. O.Schultz@acura-kliniken.com. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Pyridines, Triazoles. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Real-world data for filgotinib, a Janus kinase (JAK)1 inhibitor, are limited in patients with rheumatoid arthritis (RA).

Objectives

To explore real-world filgotinib use in patients with RA in Germany. Materials and methods This retrospective chart review included patients aged ≥ 18 years with confirmed moderate to severe RA who initiated filgotinib before December 1, 2021, with ≥ 6 months of medical records available prior to filgotinib initiation or after initial diagnosis. Patient characteristics, prior treatments, reasons for initiating/discontinuing filgotinib, disease activity, dose adjustments and concomitant treatments were recorded.

Results

In total, 301 patients from 20 German rheumatology outpatient units were included. One-third were aged ≥ 65 years and almost half had ≥ 1 cardiovascular (CV) risk factor. Most patients initiated filgotinib as monotherapy (83.7%; 12.7% of whom with glucocorticoids) and at the 200 mg dose (84.7%); higher proportions of those initiating the 100 versus 200 mg dose were aged ≥ 65 years and had renal impairment or ≥ 1 CV risk factor. Oral administration (78.4%), fast onset of action (66.8%) and administration as monotherapy (65.4%) were the most common reasons for initiating filgotinib. At 12 months, 41 (18.4%) patients had discontinued filgotinib, most commonly due to lack of effectiveness. After 6‑months of follow-up, 36.8% of patients had achieved Clinical Disease Activity Index (CDAI) remission and 45.6% had achieved CDAI low disease activity.

Conclusions

In clinical practice in Germany, reasons for initiating filgotinib in patients with RA were related to dosing flexibility and general JAK inhibitor attributes. Filgotinib was used predominantly as monotherapy and was effective and generally well tolerated; however, longer-term data in larger, prospective cohorts are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidPyridinesTriazolesHumansMaleFemaleRetrospective StudiesGermanyAgedMiddle AgedTreatment OutcomeAntirheumatic AgentsAdultDose-Response Relationship, Drug

Stichwörter der Autor:innen

Clinical trialsJanus kinase 1 inhibitorsRetrospective studiesRheumaticTherapeutic rationale

Substanzen

GLPG0634PyridinesTriazolesAntirheumatic Agents

Autor:innen und Institutionen

  • ACURA Kliniken Baden-Baden/Rheumazentrum, Rotenbachtalstraße 5, 76530, Baden-Baden, Germany. O.Schultz@acura-kliniken.com.
  • Praxis for Rheumatology and Clinical Immunology, Medical Center Baden-Baden, Baden-Baden, Germany.
  • Rheumatologische Schwerpunktpraxis Schwerin, Schwerin, Germany.
  • Ingress-Health HWM GmbH-A Cytel Company, Wismar, Germany.
  • Ingress-Health HWM GmbH-A Cytel Company, Berlin, Germany.
  • Galapagos GmbH, Basel, Switzerland.

Zitieren

APA

Schultz, O., Fiehn, C., Kneitz, C., Picker, N., Kromer, D., Zignani, M., De Leonardis, F., Orzechowski, H. D., Gurrath, M., & Krüger, K. (2025). Real-world experience with filgotinib for rheumatoid arthritis in Germany. Zeitschrift für Rheumatologie, 84(1), 39-47. https://doi.org/10.1007/s00393-024-01506-x

Vancouver

Schultz O, Fiehn C, Kneitz C, Picker N, Kromer D, Zignani M, et al. Real-world experience with filgotinib for rheumatoid arthritis in Germany. Zeitschrift für Rheumatologie. 2025;84(1):39-47. doi:10.1007/s00393-024-01506-x

BibTeX
@article{Schultz2025,
  author = {Schultz, Olaf and Fiehn, Christoph and Kneitz, Christian and Picker, Nils and Kromer, Daniel and Zignani, Monia and De Leonardis, Francesco and Orzechowski, Hans-Dieter and Gurrath, Margot and Krüger, Klaus},
  title = {Real-world experience with filgotinib for rheumatoid arthritis in Germany},
  journal = {Zeitschrift für Rheumatologie},
  year = {2025},
  volume = {84},
  number = {1},
  pages = {39--47},
  doi = {10.1007/s00393-024-01506-x}
}
Kostenlos starten →